Iodine-125 seed brachytherapy for early XXXX : a single-institution review.

@entity1 @entity137 @entity322 @entity697 @entity5
PURPOSE: We are reporting the five-year biochemical control, @entity137 profile and dosimetric parameters using iodine-125 low dose rate brachytherapy (BT) as monotherapy for early @entity5 at a single institution. MATERIAL AND METHODS: Between April 2006 and December 2010, 169 @entity1 with early @entity5 were treated with BT. Biochemical failure was defined using the Phoenix definition (nadir   +   2  ng/mL). Treatment-related morbidities, including urinary, rectal and sexual function, were measured, applying the International Prostate Symptom Score (IPSS), the 7-grade Quality of Life Scale (QoL) and medical status, the International Consultation on Incontinence Modular Questionnaire (ICIQ), the International Index of Erectile Function (IIEF-5) and the Common Terminology Criteria for Adverse Events (CTCAE v4.03). Seed migration and loss, dosimetric parameters and learning effects were also analyzed. RESULTS: Medium follow-up time was 50  months (range, 1-85 months). The five-year biochemical failure rate was 7%. @entity697 rates were 19% (grade 1) and 1% (grade 2), respectively. The overall incidence of @entity322 was 19% (mild), 16% (moderate) and   <   1% (severe). An increase in IPSS   >=    5 points was detected in 59% of @entity1 , with 38% regaining their baseline. Seed dislocation was found in 24% of @entity1 and correlated with D90 and V100. A learning curve was found for seed migration, D90 and V100. QoL correlated with the general health condition of @entity1 , @entity322 symptoms and IPSS. CONCLUSIONS: BT for early @entity5 offers excellent five-year biochemical control with low @entity137 . QoL aspects are favorable. A learning curve was detected for procedural aspects but its impact on @entity1 relevant endpoints remains inconclusive.
